Condition
Tophaceous Gout
Total Trials
5
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Completed2
Recruiting2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07089888Phase 3RecruitingPrimary
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07116746Phase 2Recruiting
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
NCT06186219Phase 1CompletedPrimary
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
NCT03965676Not ApplicableActive Not RecruitingPrimary
Evolution of Tophus and Erosions of Hands and Feet at DECT
NCT01510769Phase 3CompletedPrimary
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Showing all 5 trials